130996Development of novel drugs for Alzheimer's disease using Summit's Seglin technologyClosedFeasibility StudiesInnovate UKAlzheimer's disease (AD) is the most common form of dementia with existing AD treatments only providing symptomatic relief. There remains a high need for the development of new, disease modifying medicines that affect the progression of the disease. A hallmark of AD is the formation in the brain of tangles resulting from aggregation of the protein tau that has become hyper-phosphorylated. Summit is using its Seglin™ technology platform to target the enzyme OGA that represents a potential disease modifying approach for the treatment of AD and other neurological disorders. Summit has developed novel Seglin compounds that are potent and very selective inhibitors of the OGA enzyme. Cellular activity been demonstrated in human cells with the Seglins being shown to reduce the levels of tau phosphorylation. These inhibitors are being evaluated in AD models to confirm therapeutic effect and validate OGA as drug target for AD.